What is it used for?
AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- anagrelideanagrelide
- Form and strength
- CAPSULE · 0.5 mgCAPSULE · 0.5 mg
- Manufacturer / applicant
- TAKEDA PHARMACEUTICALS AMERICA, INC.TAKEDA PHARMACEUTICALS AMERICA, INC.
Capsules: White, opaque capsule, imprinted with " 063" in black ink. Each capsule contains 0.5 mg anagrelide equivalent to 0.61 mg anagrelide hydrochloride USP. ImprintCapsules: White, opaque capsule, imprinted with " 063" in black ink. Each capsule contains 0.5 mg anagrelide equivalent to 0.61 mg anagrelide hydrochloride USP. Imprint
Safety and clinical review
- Cardiovascular ToxicityCardiovascular Toxicity
- Pulmonary HypertensionPulmonary Hypertension
- Bleeding RiskBleeding Risk
- Pulmonary ToxicityPulmonary Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Agrylin used for?
AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Agrylin should I ask about?
CAPSULE · 0.5 mgCAPSULE · 0.5 mg
Read the primary sourceWhat determines the price of Agrylin?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Agrylin?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.